Disclosure Of Entity's Operating Segments [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166135

Concept As at
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
Disclosure of entity's operating segments [text block]
5. SECTEURS OPÉRATIONNELS
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
2,087 EUR
900,000 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method
147,000 EUR
130,000 EUR
Tax expense (income)
- EUR
4,000 EUR
Profit (loss) before tax
15,380 EUR
11,901 EUR
Profit (loss)
15,380 EUR
11,906 EUR
Assets
47,681 EUR
60,728 EUR
Investments accounted for using equity method
3,801 EUR
3,948 EUR
Liabilities
8,613 EUR
6,819 EUR
Cash flows from (used in) operating activities
12,808 EUR
13,020 EUR
Cash flows from (used in) investing activities
9,889 EUR
11,373 EUR
Cash flows from (used in) financing activities
131,000 EUR
7,838 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.